Brokerages Expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Will Announce Earnings of -$0.91 Per Share

Equities analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) to report earnings per share of ($0.91) for the current quarter, Zacks reports. Three analysts have provided estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($0.97). Atara Biotherapeutics also posted earnings per share of ($0.91) during the same quarter last year. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.45) per share for the current financial year, with EPS estimates ranging from ($3.78) to ($2.96). For the next year, analysts forecast that the firm will post earnings of ($3.08) per share, with EPS estimates ranging from ($4.08) to ($2.51). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.11. Atara Biotherapeutics had a negative return on equity of 122.18% and a negative net margin of 1,451.79%. During the same quarter in the previous year, the company posted ($0.86) earnings per share.

A number of brokerages recently weighed in on ATRA. Citigroup lowered Atara Biotherapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $15.00 to $8.00 in a research report on Monday, May 9th. Canaccord Genuity Group dropped their price target on Atara Biotherapeutics from $78.00 to $67.00 in a research note on Tuesday, March 1st. JPMorgan Chase & Co. lowered their price objective on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating for the company in a research note on Monday, March 28th. StockNews.com downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 17th. Finally, HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, January 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.43.

Shares of ATRA stock opened at $5.16 on Thursday. The firm has a market capitalization of $482.00 million, a P/E ratio of -1.42 and a beta of 1.92. Atara Biotherapeutics has a twelve month low of $4.70 and a twelve month high of $20.04. The stock’s fifty day simple moving average is $7.78 and its 200 day simple moving average is $12.68.

In other news, CFO Utpal Koppikar sold 5,582 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total value of $29,696.24. Following the transaction, the chief financial officer now owns 207,592 shares in the company, valued at $1,104,389.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Pascal Touchon sold 13,913 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total value of $74,017.16. Following the completion of the transaction, the chief executive officer now owns 486,313 shares in the company, valued at approximately $2,587,185.16. The disclosure for this sale can be found here. Insiders have sold 26,591 shares of company stock worth $141,464 in the last 90 days. Company insiders own 3.80% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Walleye Capital LLC bought a new stake in shares of Atara Biotherapeutics in the first quarter worth about $296,000. Point72 Hong Kong Ltd grew its stake in shares of Atara Biotherapeutics by 343.8% in the first quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 5,604 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Atara Biotherapeutics by 8.4% in the first quarter. Royal Bank of Canada now owns 25,962 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 2,017 shares during the last quarter. Eminence Capital LP grew its stake in shares of Atara Biotherapeutics by 19.8% in the first quarter. Eminence Capital LP now owns 1,367,710 shares of the biotechnology company’s stock worth $12,706,000 after purchasing an additional 226,253 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its stake in shares of Atara Biotherapeutics by 812.8% in the first quarter. Ensign Peak Advisors Inc now owns 163,567 shares of the biotechnology company’s stock worth $1,519,000 after purchasing an additional 145,647 shares during the last quarter.

Atara Biotherapeutics Company Profile (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.